Denosumab: an investigational drug for the management of postmenopausal osteoporosis
E Michael LewieckiNew Mexico Clinical Research & Osteoporosis Center, Albuquerque, New Mexico, USAAbstract: Denosumab (AMG 162) is an investigational fully human monoclonal antibody with a high affinity and specificity for receptor activator of nuclear factor-κB ligand (RAN...
Saved in:
Main Author: | E Michael Lewiecki |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2008
|
Subjects: | |
Online Access: | https://doaj.org/article/8bc7daaabf8d46a99e2ef8cf5c1cd09a |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Denosumab versus romosozumab for postmenopausal osteoporosis treatment
by: Tomonori Kobayakawa, et al.
Published: (2021) -
Emerging treatments for postmenopausal osteoporosis – focus on denosumab
by: Piet Geusens
Published: (2009) -
Primary osteoporosis in postmenopausal women
by: Meng-Xia Ji, et al.
Published: (2015) -
WGCNA Identification of Genes and Pathways Involved in the Pathogenesis of Postmenopausal Osteoporosis
by: Hao ML, et al.
Published: (2021) -
Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors
by: Stopeck AT, et al.
Published: (2012)